ClinicalTrials.gg
Active, not recruitingNCT05247684Updated Jul 29, 2026

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

A Phase 2 interventional study of AK112 and Carboplatin in Resectable Non-small Cell Lung Cancer, sponsored by Akeso. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung — 23 open to participants now, 30 under way, 7 of them phase 3. ivonescimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
15th of 31
90 · median 70
Started
2022
with 2 others
Phase 2
17 of 31
16 open now
Primary completion
2025-08
later than 5 of 29 live
Registered
3rd of 31
by date
Lead sponsor
9 of 31
Akeso

Among the 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by enrollment, is one of 3 that started in 2022, is one of 17 in phase 2, reaches primary completion later than 5 of the 29 other live ones, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

23 of the 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About ivonescimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC

Read the detailed description

Phase II clinical study of AK112, an anti-PD-1 and VEGF bispecific antibody, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer

03

Conditions studied

  • Resectable Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 75 years old
  2. Be able and willing to provide written and to comply with all requirements of study participation
  3. confirmed resectable stage II-IIIB NSCLC
  4. Have an (ECOG) performance status of 0 or 1
  5. Has adequate organ function
  6. All female and male subjects of must agree to use an effective method of , as determined by the Investigator, during and for 120 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Is currently participating in a study of an agent or using an investigational device
  2. Has an active disease that has required systemic treatment in the past 2 years
  3. Has an active infection requiring systemic therapy
  4. Has known active (e.g., HBsAg reactive) or (e.g., HCV RNA [qualitative] is detected)
  5. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
  6. Has received a within 30 days prior to first dose of study treatment
  7. Is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including 120 days following the last dose of study treatment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    arm 1(AK112)

    Neoadjuvant therapy was 3-4 cycles of AK112(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)

    Drug: AK112

  • Experimental
    arm 2(AK112+Carboplatin/cisplatin + paclitaxel)

    Neoadjuvant therapy was 3-4 cycles of AK112 plus Carboplatin/cisplatin + paclitaxel(Q3W), followed by surgery ,followed by adjuvant therapy for 16 cycles of AK112(Q3W)

    Drug: AK112 · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AE)

    Summary of AE incidence; summary after grading of AE according to NCI CTCAE version 5.0

    Time frame: Up to approximately 2 years

  2. Rate of surgical delays

    Proportion of subjects exceeding the maximum surgical time window

    Time frame: Up to approximately 2 years

  3. Abnormal laboratory findings of clinical significance

    Proportion of subjects with abnormal and clinically significant results including routine blood tests, blood biochemical tests, coagulation tests, thyroid function tests, routine urine tests, pregnancy tests, etc.

    Time frame: Up to approximately 2 years

  4. Major pathological response (MPR)

    Proportion of subjects with ≤10% residual live tumor cells in resected primary tumor and lymph nodes

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. R0 resection rate

    Proportion of subjects with pathologically complete resection of primary tumors

    Time frame: Up to approximately 2 years

  2. Tumor descending stage rate

    Proportion of subjects with the most recent tumor staging prior to surgery (using TNM staging version 8) who were down-staged relative to baseline

    Time frame: Up to approximately 2 years

  3. Pathological complete response (pCR)

    Proportion of subjects with no residual tumor in the resected primary tumor and lymph nodes

    Time frame: Up to approximately 2 years

  4. Overall survival (OS)

    Time from first dose until death from any cause

    Time frame: Up to approximately 2 years

  5. Event free survival (EFS)

    Time from first dose to the occurrence of any of the following events, whichever occurs first: disease progression, local recurrence or distant metastasis or death from any cause, as assessed according to RECIST v1.1.

    Time frame: Up to approximately 2 years

  6. Objective response rate (ORR)

    ORR is the proportion of subjects with CR or PR, based on RECIST v1.1.

    Time frame: Up to approximately 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Aug 2025, 41 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 41 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2022
First posted
Feb 21, 2022
StartActual
Feb 20, 2022
Primary completionActual
Aug 18, 2025
CompletionEst.
Dec 31, 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05247684
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Feb 20, 2022
Primary completion
Aug 18, 2025
Completion
Dec 31, 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

Changli Wang
principal investigator · Tianjin Medical University Cancer Institute and Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion